DE60136656D1 - Rationell entworfene Antikörper - Google Patents
Rationell entworfene AntikörperInfo
- Publication number
- DE60136656D1 DE60136656D1 DE60136656T DE60136656T DE60136656D1 DE 60136656 D1 DE60136656 D1 DE 60136656D1 DE 60136656 T DE60136656 T DE 60136656T DE 60136656 T DE60136656 T DE 60136656T DE 60136656 D1 DE60136656 D1 DE 60136656D1
- Authority
- DE
- Germany
- Prior art keywords
- antibodies
- rationally designed
- fragments
- designed antibodies
- terminal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000012634 fragment Substances 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/505—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/14—Erythropoietin [EPO]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25144800P | 2000-12-05 | 2000-12-05 | |
US28888901P | 2001-05-04 | 2001-05-04 | |
US29406801P | 2001-05-29 | 2001-05-29 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60136656D1 true DE60136656D1 (de) | 2009-01-02 |
Family
ID=27400449
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60118023T Expired - Lifetime DE60118023T2 (de) | 2000-12-05 | 2001-12-05 | Rationell entworfene antikörper |
DE60136656T Expired - Lifetime DE60136656D1 (de) | 2000-12-05 | 2001-12-05 | Rationell entworfene Antikörper |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60118023T Expired - Lifetime DE60118023T2 (de) | 2000-12-05 | 2001-12-05 | Rationell entworfene antikörper |
Country Status (11)
Country | Link |
---|---|
US (3) | US7482435B2 (de) |
EP (4) | EP1642910B1 (de) |
AT (3) | ATE544785T1 (de) |
AU (2) | AU2002234001B2 (de) |
CA (1) | CA2436671C (de) |
CY (1) | CY1112639T1 (de) |
DE (2) | DE60118023T2 (de) |
DK (1) | DK1642910T3 (de) |
ES (3) | ES2316919T3 (de) |
PT (1) | PT1642910E (de) |
WO (1) | WO2002046238A2 (de) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY126795A (en) | 1998-10-23 | 2006-10-31 | Amgen K A Inc | Dimeric thrombopoietic peptide mimetics binding to mp1 receptor and having thrombopoietic activity. |
US7396917B2 (en) | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
AU2003295623B2 (en) * | 2000-12-05 | 2008-06-05 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
EP1642910B1 (de) | 2000-12-05 | 2012-02-08 | Alexion Pharmaceuticals, Inc. | Rationell entworfene Antikörper |
US7332474B2 (en) * | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
EP1545608A4 (de) * | 2002-06-28 | 2006-09-13 | Centocor Inc | Ch1-deletierte säugetier-mimetikörper, zusammensetzungen, verfahren und anwendungen |
WO2005081687A2 (en) * | 2003-09-30 | 2005-09-09 | Centocor, Inc. | Human hinge core mimetibodies, compositions, methods and uses |
UA89481C2 (uk) * | 2003-09-30 | 2010-02-10 | Центокор, Инк. | Еритропоетинові міметичні шарнірно-серцевинні міметитіла людини, композиції, способи та застосування |
US20070116710A1 (en) * | 2004-02-03 | 2007-05-24 | Leonard Bell | Methods of treating hemolytic anemia |
US20050169921A1 (en) * | 2004-02-03 | 2005-08-04 | Leonard Bell | Method of treating hemolytic disease |
US7393662B2 (en) | 2004-09-03 | 2008-07-01 | Centocor, Inc. | Human EPO mimetic hinge core mimetibodies, compositions, methods and uses |
MX340784B (es) | 2006-03-15 | 2016-07-26 | Alexion Pharma Inc | Inhibidores de complemento para usarse en el tratamiento de pacientes con hemoglobinuria paroxística nocturna. |
JP2010515463A (ja) * | 2007-01-12 | 2010-05-13 | シー レーン バイオテクノロジーズ, エルエルシー | 配座的に束縛されたポリペプチド配列のコンビナトリアルライブラリー |
US20090022729A1 (en) * | 2007-04-13 | 2009-01-22 | Nigel Mackman | Methods and compositions for treating cardiac dysfunctions |
US20090054332A1 (en) * | 2007-06-21 | 2009-02-26 | Conjuchem Biotechnologies, Inc. | Thombopoietin peptide conjugates |
CN109045296A (zh) | 2008-11-10 | 2018-12-21 | 阿雷克森制药公司 | 用于治疗补体相关障碍的方法和组合物 |
MX2011008936A (es) | 2009-02-24 | 2011-09-21 | Alexion Pharma Inc | Anticuerpos que contienen peptidos terapeuticos mimeticos de tpo/epo. |
WO2012012759A2 (en) | 2010-07-22 | 2012-01-26 | The Regents Of The University Of California | Anti-tumor antigen antibodies and methods of use |
TW201241008A (en) * | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
UA114077C2 (xx) * | 2010-11-19 | 2017-04-25 | Нейтралізуюче антитіло проти ccl20 | |
HUE053669T2 (hu) | 2012-12-05 | 2021-07-28 | Novartis Ag | Készítmények és eljárások EPO-t célzó antitestekre |
BR112016002435A8 (pt) | 2013-08-07 | 2020-09-29 | Alexion Pharma Inc | proteínas biomarcadoras da síndrome urêmica hemolítica atípica |
CA2971288A1 (en) | 2015-02-02 | 2016-08-11 | The University Of Birmingham | Targeting moiety peptide epitope complexes having a plurality of t-cell epitopes |
CN107922975B (zh) | 2015-08-12 | 2022-06-28 | 诺华股份有限公司 | 治疗眼科病症的方法 |
BR112018010937A2 (pt) | 2015-12-04 | 2018-12-04 | Novartis Ag | composições de anticorpos enxertados com citocina e métodos de uso para imunorregulação |
KR20180100132A (ko) | 2016-01-08 | 2018-09-07 | 이온타스 엘티디 | 변형된 다양성 스캐폴드 도메인을 갖는 결합 멤버 |
JOP20190271A1 (ar) | 2017-05-24 | 2019-11-21 | Novartis Ag | بروتينات مطعّمة بسيتوكين- الجسم المضاد وطرق الاستخدام للاضطرابات المتعلقة بالمناعة |
GB201711208D0 (en) | 2017-07-12 | 2017-08-23 | Iontas Ltd | Ion channel inhibitors |
WO2019012015A1 (en) | 2017-07-12 | 2019-01-17 | Iontas Limited | POTASIC CHANNEL INHIBITORS |
CN108623681B (zh) * | 2018-05-04 | 2019-05-24 | 珠海泰诺麦博生物技术有限公司 | 一种抗破伤风毒素的中和抗体及应用 |
CN113966345A (zh) | 2019-06-12 | 2022-01-21 | 诺华股份有限公司 | 利钠肽受体1抗体及使用方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0088994B1 (de) | 1982-03-15 | 1991-06-19 | Schering Corporation | Hybride DNS, damit hergestellte Bindungszusammensetzung und Verfahren dafür |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4783330A (en) | 1984-11-15 | 1988-11-08 | New England Medical Center Hospitals, Inc. | Monoclonal antibodies to activated platelets |
US5618920A (en) | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
US5965405A (en) | 1988-04-16 | 1999-10-12 | Celltech Limited | Method for producing Fv fragments in eukaryotic cells |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
US20020086843A1 (en) | 1989-03-01 | 2002-07-04 | Daiichi Pure Chemicals Co., Ltd. | Physiologically active polypeptide and DNA |
US5260417A (en) | 1989-04-03 | 1993-11-09 | Genetics Institute, Inc. | Megakaryocyte growth promoting activity protein |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
US5506107A (en) | 1991-05-10 | 1996-04-09 | Genentech, Inc. | Selecting ligand agonists and antagonists |
WO1993002190A1 (en) | 1991-07-15 | 1993-02-04 | The Wellcome Foundation Limited | Production of antibodies |
JP2665850B2 (ja) | 1991-11-14 | 1997-10-22 | 塩野義製薬株式会社 | hBNPのC端を認識するモノクロ−ナル抗体 |
AU4190893A (en) | 1992-07-17 | 1994-01-20 | Suntory Limited | Megakaryocyte differentiation factor |
AU6235294A (en) * | 1993-02-02 | 1994-08-29 | Scripps Research Institute, The | Methods for producing polypeptide binding sites |
DE69435126D1 (de) * | 1993-10-19 | 2008-10-02 | Scripps Research Inst | Synthetische humane neutralisierende monoklonale antikörper gegen hiv |
US5773569A (en) * | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5598435A (en) | 1993-12-23 | 1997-01-28 | British Telecommunications Public Limited Company | Digital modulation using QAM with multiple signal point constellations not equal to a power of two |
US5919758A (en) | 1994-03-22 | 1999-07-06 | Beth Israel Deaconess Medical Center | Modified polypeptides with altered biological activity |
WO1995029690A1 (en) * | 1994-04-29 | 1995-11-09 | The Trustees Of The University Of Pennsylvania | Biologically active peptides and methods of identifying the same |
US5885574A (en) | 1994-07-26 | 1999-03-23 | Amgen Inc. | Antibodies which activate an erythropoietin receptor |
US5593666A (en) | 1994-08-16 | 1997-01-14 | The University Of Tennessee Research Corp. | Methods and compositions for treating thrombocytopenia |
DE19513676A1 (de) | 1995-04-11 | 1996-10-17 | Behringwerke Ag | Cytoplasmatische Expression von Antikörpern, Antikörperfragmenten und Antikörperfragmentfusionsmolekülen in E.coli |
US5869451A (en) * | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
AU6046696A (en) * | 1995-06-07 | 1996-12-30 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
CN1315870C (zh) * | 1995-06-07 | 2007-05-16 | 葛兰素集团有限公司 | 结合血小板生成素受体的肽和化合物 |
WO1997032900A1 (en) | 1996-03-04 | 1997-09-12 | Scios Inc. | ASSAY AND REAGENTS FOR QUANTIFYING hBNP |
US5932546A (en) | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
US6737249B1 (en) | 1997-08-22 | 2004-05-18 | Genentech, Inc. | Agonist antibodies |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
EP1030684A4 (de) * | 1997-11-14 | 2004-09-15 | Euro Celtique Sa | Modifizierte antikörper mit verstärkter fähigkeit eine anti-idiotypische antwort auszulösen |
AUPP221098A0 (en) * | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
MY126795A (en) * | 1998-10-23 | 2006-10-31 | Amgen K A Inc | Dimeric thrombopoietic peptide mimetics binding to mp1 receptor and having thrombopoietic activity. |
WO2000061637A1 (en) * | 1999-04-14 | 2000-10-19 | Smithkline Beecham Corporation | Erythropoietin receptor antibodies |
US7396917B2 (en) * | 2000-12-05 | 2008-07-08 | Alexion Pharmaceuticals, Inc. | Rationally designed antibodies |
EP1642910B1 (de) | 2000-12-05 | 2012-02-08 | Alexion Pharmaceuticals, Inc. | Rationell entworfene Antikörper |
WO2002078612A2 (en) * | 2001-04-02 | 2002-10-10 | Euro-Celtique S.A. | Thrombopoietin (tpo) synthebody for stimulation of platelet production |
-
2001
- 2001-12-05 EP EP05076105A patent/EP1642910B1/de not_active Expired - Lifetime
- 2001-12-05 DE DE60118023T patent/DE60118023T2/de not_active Expired - Lifetime
- 2001-12-05 DE DE60136656T patent/DE60136656D1/de not_active Expired - Lifetime
- 2001-12-05 EP EP01985007A patent/EP1370589B1/de not_active Expired - Lifetime
- 2001-12-05 EP EP04077553A patent/EP1498429A3/de not_active Withdrawn
- 2001-12-05 AT AT05076105T patent/ATE544785T1/de active
- 2001-12-05 WO PCT/US2001/047656 patent/WO2002046238A2/en not_active Application Discontinuation
- 2001-12-05 US US10/006,593 patent/US7482435B2/en not_active Expired - Fee Related
- 2001-12-05 ES ES04077554T patent/ES2316919T3/es not_active Expired - Lifetime
- 2001-12-05 AU AU2002234001A patent/AU2002234001B2/en not_active Ceased
- 2001-12-05 AT AT01985007T patent/ATE320450T1/de not_active IP Right Cessation
- 2001-12-05 DK DK05076105.5T patent/DK1642910T3/da active
- 2001-12-05 ES ES01985007T patent/ES2258558T3/es not_active Expired - Lifetime
- 2001-12-05 PT PT05076105T patent/PT1642910E/pt unknown
- 2001-12-05 AT AT04077554T patent/ATE414720T1/de not_active IP Right Cessation
- 2001-12-05 CA CA2436671A patent/CA2436671C/en not_active Expired - Fee Related
- 2001-12-05 EP EP04077554A patent/EP1589034B1/de not_active Expired - Lifetime
- 2001-12-05 AU AU3400102A patent/AU3400102A/xx active Pending
- 2001-12-05 ES ES05076105T patent/ES2380367T3/es not_active Expired - Lifetime
-
2009
- 2009-01-26 US US12/321,828 patent/US8771932B2/en not_active Expired - Fee Related
-
2012
- 2012-03-12 CY CY20121100251T patent/CY1112639T1/el unknown
-
2014
- 2014-04-29 US US14/264,975 patent/US9409964B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20030049683A1 (en) | 2003-03-13 |
CA2436671A1 (en) | 2002-06-13 |
EP1589034A3 (de) | 2005-11-02 |
ATE414720T1 (de) | 2008-12-15 |
US20100041012A1 (en) | 2010-02-18 |
EP1642910B1 (de) | 2012-02-08 |
ATE544785T1 (de) | 2012-02-15 |
ES2380367T3 (es) | 2012-05-11 |
EP1589034B1 (de) | 2008-11-19 |
AU2002234001B2 (en) | 2008-05-01 |
EP1642910A1 (de) | 2006-04-05 |
ES2258558T3 (es) | 2006-09-01 |
EP1370589B1 (de) | 2006-03-15 |
AU3400102A (en) | 2002-06-18 |
DE60118023D1 (de) | 2006-05-11 |
EP1498429A3 (de) | 2005-08-03 |
WO2002046238A3 (en) | 2003-07-10 |
CA2436671C (en) | 2015-02-03 |
ES2316919T3 (es) | 2009-04-16 |
WO2002046238A2 (en) | 2002-06-13 |
US20150004700A1 (en) | 2015-01-01 |
ATE320450T1 (de) | 2006-04-15 |
EP1589034A2 (de) | 2005-10-26 |
DK1642910T3 (da) | 2012-05-07 |
PT1642910E (pt) | 2012-03-22 |
EP1370589A2 (de) | 2003-12-17 |
CY1112639T1 (el) | 2016-02-10 |
DE60118023T2 (de) | 2006-12-28 |
EP1498429A2 (de) | 2005-01-19 |
US8771932B2 (en) | 2014-07-08 |
US7482435B2 (en) | 2009-01-27 |
US9409964B2 (en) | 2016-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE414720T1 (de) | Rationell entworfene antikörper | |
WO2005060642A3 (en) | Rationally designed antibodies | |
WO2004050017A3 (en) | Rationally designed antibodies | |
WO2005082004A3 (en) | Rationally designed antibodies having a domain-exchanged scaffold | |
HK1109160A1 (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours | |
ID27784A (id) | Peptida-peptida penghambat hepatitis c | |
CO5611160A2 (es) | Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos | |
IL160001A0 (en) | Peptide based multimeric targeted contrast agents and methods for the preparation thereof | |
ATE348632T1 (de) | Prion protein peptide und deren verwendung | |
IL195649A0 (en) | Compositions comprising anti-??v??3 recombinant human antibodies and nucleic acids encoding the same | |
DK0914144T3 (da) | Terapeutiske anvendelser af BPI-protein-produkter til human meningokokæmi | |
AU2002308348A1 (en) | Ganglioside-associated recombinant antibodies and the use thereof in the diagnosis and treatment of tumours | |
WO1999003881A3 (fr) | Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique | |
NO20073914L (no) | Biologisk aktive peptider | |
FR2810985B1 (fr) | Peptides lineaires amphipathiques et les compositions les contenant | |
WO2004108078A3 (en) | Rationally designed antibodies | |
ATE328003T1 (de) | Chimäre nukleinsäuren und polypeptide aus lyssavirus | |
Critical Care Society of South Africa Working Group | Severe sepsis and the role of novel therapeutic agents. Position statement of the Critical Care Society of South Africa on severe sepsis and the role of novel therapeutic agents such as drotrecogin alfa (activated) | |
CY1113344T1 (el) | Χρηση της il-21 στον καρκινο και μονοκλωνικα αντισωματα για θεραπευτικη αγωγη στερεων καρκινων | |
HK1044796A1 (zh) | 為新穎兼平切的可卡因和安菲他明調節轉錄物(cart)蛋白及其相應的平切的可卡因和安菲他明調節轉錄物縮多氨酸進行編碼的核酸及該核酸的醫療和診斷用途 | |
ITRM960808A1 (it) | Immunoconiugati comprendenti anticorpi monoclonali umani o frammenti di essi per diagnosi in vivo e terapia | |
IT1254976B (it) | Fattori chemiotattici |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |